(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 14 February 2002 (14.02.2002)

PCT

(10) International Publication Number WO 02/012336 A3

(51) International Patent Classification⁷: A61K 38/18, C12N 5/06

(21) International Application Number: PCT/US01/04192

(22) International Filing Date: 9 February 2001 (09.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/635,368 9 August 2000 (09.08.2000) US

(71) Applicant (for all designated States except US): CURIS, INC. [US/US]; 45 Moulton Street, Cambridge, MA 02138 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WANG, Monica [US/US]; 183 West Shore Drive, Marblehead, MA 01945 (US). PANG, Kevin [US/US]; 53 Hill Road, #710, Belmont, MA 02478 (US).

(74) Agents: VARMA, Anita et al.; Foley, Hoag & Eliot, LLP, Patent Group, One Post Office Square, Boston, MA 02109 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 14 August 2003

(15) Information about Correction: Previous Correction:

see PCT Gazette No. 41/2002 of 10 October 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



O 02/012336 A3

(54) Title: TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE

(57) Abstract: The present invention relates to $TGF\beta$ therapeutics, $TGF\beta$ proteins or a combination of $TGF\beta$ proteins which are capable of stimulating growth and/or differentiation of pancreatic tissue. The invention also relates to pharmaceutical compositions comprising such proteins and/or therapeutics, methods for using such proteins and/or therapeutics in culturing pancreatic tissue and cells and methods for administering such proteins and/or therapeutics to a subject.

Internat pplication No PCT/US 01/04192

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/18 C12N5/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data, SEQUENCE SEARCH

Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
X A	US 5 604 204 A (AMMANN ARTHUR J 18 February 1997 (1997-02-18) column 5, line 59 -column 6, lin claims 1,2,7; figures 1A,1B column 7, line 33 - line 54		10,11 1-4
X A	US 5 409 896 A (AMMANN ARTHUR J 25 April 1995 (1995-04-25) column 6, line 3 - line 39; cla figures 1A,1B	•	10 1–4
X A	US 5 705 477 A (ROBERTS ANITA B 6 January 1998 (1998-01-06) column 2, line 12 - line 25; cla		10 14–16
X A	US 5 656 587 A (ROBERTS ANITA B 12 August 1997 (1997-08-12) column 2, line 10 - line 24; cla		10 14-16
° Special ca 'A' docume consic 'E' earlier filing c 'L' docume which citatio 'O' docume other i 'P' docume later ti	ner documents are listed in the continuation of box C. Itegories of cited documents: In the defining the general state of the art which is not lered to be of particular relevance document but published on or after the international late. In the defining the general state of the art which is not lered to be of particular relevance document but published on or after the international late. In the defining the general state of the internation of the internation of the international filing date but the provity date claimed.	T* later document published after the integration or priority date and not in conflict with cited to understand the principle or the invention *X* document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the decannot be considered to involve an indocument of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art. *&* document member of the same patent.	ernational filing date the application but eory underlying the claimed invention t be considered to cument is taken alone claimed invention ventive step when the ore other such docu— us to a person skilled
1	2 February 2003	19/02/2003	
Name and r	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Charles, D	

Internati plication No
PCT/US 01/04192

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MIRALLES FRANCISCO ET AL: "TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2" JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 143, no. 3, 2 November 1998 (1998-11-02), pages 827-836, XP002148144 ISSN: 0021-9525 page 828, left-hand column, paragraph 1 page 830, right-hand column, paragraph 4 -page 832, left-hand column, paragraph 2 page 834, left-hand column, paragraph 1 -page 835, left-hand column, paragraph 1	14-17
X	SANVITO F ET AL: "TGF-beta-1 influences the relative development of the exocrine and endocrine pancreas in vitro" DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 120, no. 12, 1994, pages 3451-3462, XP002148143 ISSN: 0950-1991 page 3451, right-hand column, paragraph 1 page 3457, left-hand column, paragraph 3 -page 3458, left-hand column, paragraph 1 page 3459, right-hand column, paragraph 2 -page 3460, right-hand column, paragraph 3	14-17
X	ALVAREZ A ET AL: "Regulation of pancreatic duct cell growth by transforming growth factor beta (TGFbeta) in vitro" GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), page A1375 XP000925857 ISSN: 0016-5085 the whole document	14-17
X,P	WO 00 47243 A (WANG MONICA ;GUICHERIT OIVEN (US); ONTOGENY INC (US); PANG KEVIN () 17 August 2000 (2000-08-17) the whole document	2-4,10, 14-16
E	WO 01 39784 A (ZULEWSKI HENDRIK; VALLEJO MARIO (ES); ABRAHAM ELIZABETH J (US); GE) 7 June 2001 (2001-06-07) page 1, line 10 - line 15; claims 1,6,44,46,47 page 29, line 31 - line 34	14-16

Internati pplication No PCT/US 01/04192

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	101/03 01/04192
Category °		Relevant to claim No.
А	EP 0 542 679 A (CIBA GEIGY AG) 19 May 1993 (1993-05-19) page 3, line 17 - line 20; claims 1,15 page 4, line 44 - line 46 page 7, line 17 - line 19 page 7, line 49 - line 54	1-3,5, 14,15,17

al application No.
PCT/US 01/04192

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 2-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: $1,7-9,13,19-21$ because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report
1	covers only those claims for which fees were paid, specifically claims Nos.:
	1
4	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	k on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,7-9,13,19-21

Present claims 1, 7-9, 13, 19-21 relate to compounds defined by reference to a desirable characteristic or property, namely "TGF-beta therapeutic" (Claims 1, 7-9, 13, 19-21) and "TGF-beta agonist" (Claims 7, 19).

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds TGF-beta protein (thus a protein with TGF-beta activity). Since no example of agonists has been given neither in the Claims nor in the Description, no search has been performed regarding this agent.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Infanation on patent family members

Internal pplication No
PCT/US 01/04192

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5604204	A	18-02-1997	US	5409896	A	25-04-1995
			US	5158934		27-10-1992
— 			US	5422340 	A 	06-06-1995
US 5409896	Α	25-04-1995	US	5158934		27-10-1992
			US	5604204		18-02-1997
			US	5422340	A 	06-06-1995
US 5705477	Α	06-01-1998	US	5104977		14-04-1992
			US	5656587		12-08-1997
			ΑT	76299		15-06-1992
			AU	565347		10-09-1987
			AU	2120183		04-04-1984
			CA DE	1223198 3382562		23-06-1987
			EP	0105014		25-06-1992 04-04-1984
			JP	6065680		24-08-1994
			JP	59501905		15-11-1984
			WO	8401106		29-03-1984
US 5656587	A	 12-08-1997	 US	5104977	Δ	 14-04-1992
00 0000007	,,	12 00 1997	US	5705477		06-01-1998
			AT	76299		15-06-1992
			AU	565347		10-09-1987
			AU	2120183		04-04-1984
			CA	1223198		23-06-1987
			DE	3382562	D1	25-06-1992
			EP	0105014		04-04-1984
			JP	6065680		24-08-1994
			JP	59501905		15-11-1984
			WO	8401106	A1 	29-03-1984
WO 0047243	Α	17-08-2000	AU	2988900		29-08-2000
			MO	0047243		17-08-2000
	·		US 	6496887	B1 	17-12-2002
WO 0139784	Α	07-06-2001	AU	1817301		12-06-2001
			EP	1257282		20-11-2002
			WO	0139784		07-06-2001
			US	2001024824		27-09-2001
			US US	2001046489 2002164307		29-11-2001
	<u>-</u>					07-11-2002
EP 0542679	Α	19-05-1993	AU	2738392		13-05-1993
			CA EP	2082450 0542679		12-05-1993
			FI	925086		19-05-1993 12-05-1993
			JP	5306297		12-05-1993
			MX	9206456		01-07-1993
			NO	924323		12-05-1993
			NZ	245047		27-04-1995
			ZA	9208647		· 1550